CD274 and cancer: Elevated PD-L1 expression in cancer cells might lead to the suppression of the therapeutic efficacy of PD-1 or PD-L1 antibody, both of which are approved by the FDA as an immune checkpoint blockade (ICB) therapeutic strategies to restore T-cell function [40–42].